8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 3, 2015
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
|
| | | | |
|
Massachusetts | | 1-14041 | | 04-2882273 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
|
| | |
|
400 Wood Road, Braintree MA | | 02184 |
(Address of principal executive offices) | | (Zip Code)
|
Registrant’s telephone number, including area code 781-848-7100
(Former name or former address, if changed since last report.)
|
| |
|
| |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Departure of Principal Accounting Officer
On September 3, 2015 Haemonetics Corporation (the “Company”) and Susan Hanlon mutually agreed that Ms. Hanlon will leave Haemonetics to pursue other professional opportunities once her successor has been identified and successful transition of her responsibilities is completed. Ms. Hanlon has agreed to continue in her current capacity as Vice President, Finance and the Company’s principal accounting officer until that time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
|
| | |
| HAEMONETICS CORPORATION |
| (Registrant) |
| | |
| | |
Date: September 3, 2015 | By | /s/ Christopher Lindop |
| | Christopher Lindop, Executive Vice President |
| | and Chief Financial Officer |